Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 29, 2023 00:00 ET | Source: Faron Pharmaceuticals Oy

Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia

ODD further strengthens bexmarilimab program by offering clinical development and commercialization benefitsExpected completion of dose escalation, readout of enrichment cohorts, and Phase II...
August 04, 2023 08:00 ET | Source: Faron Pharmaceuticals Oy

Faron Pharmaceuticals Notice of Half-Year Financial Results

TURKU, Finland and BOSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via...
August 02, 2023 08:00 ET | Source: Faron Pharmaceuticals Oy

Faron to Participate in Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference

Management to present on Thursday, August 10 at 12:30-12:55 PM Eastern Time at the InterContinental Boston Hotel in Boston, MassachusettsPresentation will highlight recent updated positive Phase I/II...
July 19, 2023 04:54 ET | Source: Faron Pharmaceuticals Oy

Faron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS

TURKU, Finland and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via...
July 19, 2023 03:00 ET | Source: Faron Pharmaceuticals Oy

Faron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS BEXMAB Study Update

Three of five patients in the 6 mg/kg bexmarilimab + azacitidine doublet cohort achieved objective responses (CR and mCR)Eight of 15 objective responses observed in all three doublet dosing cohortsOne...
January 29, 2018 07:01 ET | Source: Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy: FDA grants Fast Track Designation to Faron for Traumakine®

Faron Pharmaceuticals Ltd("Faron" or the "Company") FDA grants Fast Track Designation to Faron for Traumakine® Faron's wholly-owned product for Acute Respiratory Distress Syndrome on track...
January 24, 2018 07:00 ET | Source: Faron Pharmaceuticals Oy

FDA has approved Faron's Traumakine® IND

Faron Pharmaceuticals Ltd("Faron" or the "Company") FDA has approved Faron's Traumakine® IND TURKU - FINLAND, 24 January 2018 - Faron Pharmaceuticals Ltd ("Faron") (AIM: FARN), the...
December 19, 2017 07:01 ET | Source: Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy: Study update: Traumakine® Phase II/III INFORAAA trial for Multi-Organ Failure receives recommendation from IDMC

Faron Pharmaceuticals Ltd("Faron" or the "Company") Study update: Traumakine® Phase II/III INFORAAA trial for Multi-Organ Failure receives recommendation from IDMC First recommendation...
December 11, 2017 07:00 ET | Source: Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy: Recruitment completed in Traumakine INTEREST Trial

Faron Pharmaceuticals Ltd("Faron" or the "Company") Recruitment completed in Traumakine INTEREST Trial The upcoming read-out will collate intact 90 day morbidity/mortality data alongside 28...
December 01, 2017 07:00 ET | Source: Faron Pharmaceuticals Oy

Faron Pharmaceuticals Oy: Appointment of Chief Commercial Officer

Faron Pharmaceuticals Oy("Faron" or the "Company") Appointment of Chief Commercial Officer Dr. Juhana Heinonen, previously AstraZeneca's Global Marketing Director, to steer...